Skip to content
PICO Portalanswers from OpenAlex

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

PaperCitations, authors & open-access status

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is a paper indexed in PICO Portal from OpenAlex.

How many citations does Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group have?

PICO Portalcitation count

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has 39 citations in the OpenAlex counts PICO Portal stores.

When was Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group published?

PICO Portalyear

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has 2010 year in the PICO Portal index.

What is the open-access status of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

PICO Portaloa status

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group has gold oa status in the PICO Portal index.

What is the DOI of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

PICO Portaldoi

The DOI for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.

What is the PMID of Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

PICO Portalpmid

The PMID for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.

What is the OpenAlex record for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group?

PICO Portalopenalex

The OpenAlex for Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial